Advertisement
U.S. markets close in 5 hours 2 minutes
Advertisement

Nutra Pharma Corp. (NPHC)

Other OTC - Other OTC Delayed Price. Currency in USD
0.00000.0000 (0.00%)
As of 11:24AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.0000
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range0.0000 - 0.0010
Volume2,575
Avg. Volume90,198
Market Cap7,596
Beta (5Y Monthly)-22.06
PE Ratio (TTM)∞
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NPHC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NUTRA PHARMA CORP
    Analyst Report: Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
    Rating
    Fair Value
    Economic Moat
    15 hours agoMorningstar
View more

  • We're sorry we weren't able to find anything about this topic.